YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.

Ling-Chen Li,Xie-Wan Chen,Ling Fang,Chun-Li Jian,Yong-Xin Yu,Xing-Yun Liao,Jian-Guo Sun

Canadian respiratory journal（2023）

引用 0|浏览1

暂无评分

摘要

YAP1 mediates immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population. YAP1 is a novel negative biomarker of ICIs treatment in EGFR-mutant NSCLC population. . This trial is registered with NCT03513666.

查看译文

关键词

immune checkpoint inhibitors,lung cancer,yap1,novel negative biomarker,egfr-mutant,non-small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要